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The discovery by Morris et al. (1994) of the genes contributing to the t(2;5)(p23;q35) translo-
cation has laid the foundation for a molecular based recognition of anaplastic large cell
lymphoma and highlighted the need for a further stratiﬁcation ofT-cell neoplasia. Likewise
the detection of anaplastic lymphoma kinase (ALK) genetic lesions among many human
cancers has deﬁned unique subsets of cancer patients, providing new opportunities for
innovative therapeutic interventions. The objective of this review is to appraise the mol-
ecular mechanisms driving ALK-mediated transformation, and to maintain the neoplastic
phenotype. The understanding of these events will allow the design and implementation
of novel tailored strategies for a well-deﬁned subset of cancer patients.
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INTRODUCTION
The concept of anaplastic large cell lymphoma (ALCLs) has
changed over the years as a result of a fruitful stream of new
information and novel understanding about the cell of origin,
biology, genetics, and clinical features of these neoplasms. Most
importantly, the discovery of anaplastic lymphoma kinase (ALK)
fusion chimera, among ALCLs, has provided the basis for the def-
inition of a unique subgroup among peripheral T-cell lymphoma
(PTCL) and set the stage for the identiﬁcation of new entities,
some of which still remain provisional within the current WHO
Classiﬁcation of tumors of hematopoietic and lymphoid tissues.
Indeed, the discovery of the Nucleophosmin (NPM)–ALK
fusion, in many but not entirely systemic ALCL, have led
to the recognition that ALCLs are biologically and clinically
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heterogeneous. In fact, it has likewise become evident that ALK+
ALCLs,most commonly seen in children and young adults, display
a more favorable prognosis. On the contrary, ALK− ALCLs have
a more aggressive clinical course and could represent a distinct
morphologic variant among PTCL, not otherwise speciﬁed, NOS
(PTCL–NOS; Delsol et al., 2008).
Although the molecular stratiﬁcation of ALCLs has provided
objective criteria for precise diagnoses, many issues remain open.
As a matter of fact, we do not know the mechanisms leading to
the transformation of ALK−ALCLs, including those involving the
skin primarily (cALCL), or whether various entities amongALCLs
somehow share common pathogenetic features and if putative
relationship(s)with other T-cell lymphomamay exist. These issues
are critical for the design efﬁcient therapies, tailored to unique
subsets, targeting individual biological and genetics defects.
The main objective of this review is to undertake a systematic
appraisal of ALK deregulation in human cancers and in particular
in ALCLs, with the intent of discussing novel targeted therapies
and/or personalized therapeutic modalities.
PERIPHERAL T-CELL LYMPHOMA
T-non-Hodgkin lymphoma (NHLs) include a large number of
neoplasia, most likely representing the neoplastic counterpart of
functionally distinct T-cells, transformedbyunique but still largely
unknown genetic defects. Among those derived from mature T-
lymphocytes, two subsets have been described, known otherwise
as PTCL speciﬁed and NOS. These lymphoma are overall quite
rare, ranging from 12 to 15% among all NHL in Western pop-
ulations (Table 1; Vose et al., 2008). Many of them display a
great variability in their clinical, morphological, immunopheno-
typic, cytogenetics, and molecular features. PTCL–NOS is the
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Table 1 | Geographic distribution of anaplastic large cell lymphoma
compared to peripheralT-cell lymphoma, not-otherwise specified
(PTCL–NOS).
PTCL
PTCL–NOS ALCL
GEOGRAPHIC DISTRIBUTION (%)
USA 3 2
Canada 1 3
South Africa 8 3
England 8 2
Germany 4 1
France 4 3
Switzerland 6 0
Hong Kong 10 3
most common (30–40%), followed by the angioimmunoblastic
(AITL) and ALCLs. ALCLs occur in∼2–8% of NHL in adults and
represent 15–30% of all high-grade lymphoma in children.
Systemic ALCLs are classiﬁed as de novo and secondary
(anaplastic transformation of other lymphoma). De novo ALK+
ALCLs are clinically aggressive lymphoma that frequently occur
within the ﬁrst three decades of life, with a typical male predom-
inance. They often present as a stage III–IV disease, with systemic
symptoms, and extranodal involvement (60%; Falini et al., 1999;
Stein et al., 2000). ALK− ALCLs arise in older patients (most
commonly at sixth decade of life), with a slight predominance
in males (Savage et al., 2008), and high International prognos-
tic index (IPI) scores (Tilly et al., 1997; see Table 2). Extranodal
involvement is relatively common with cutaneous, hepatic, or gas-
trointestinal sites most frequently engaged. ALK− ALCLs, when
compared to ALK+ ALCLs, display a worse clinical presentation
and outcome, meanwhile they have a relatively better overall sur-
vival rate than PTCL–NOS (36 versus 20%, respectively; Vose
et al., 2008). The more favorable clinical outcome of the ALK+
ALCLs (Savage et al., 2008) has been associated to the age of
occurrence and to the driving molecular defects, in particular to
ALK fusions. When ALCL patients are however studied taking
into account the age and/or other clinical parameters, ALK+ and
ALK− ALCLs display analogous clinical features, suggesting that
relevant clinical factors may have critical implications on their
outcome. Nevertheless, it is unclear whether these clinical features
are due to and/or associated to restricted defects occurring at dif-
ferent ages and/or accumulate overtime. Besides the well-deﬁned
primary chromosomal translocations, ALK+ ALCLs carry fre-
quent secondary chromosomal imbalances, although their com-
plex karyotype is substantially less complex than those observed
in ALK− ALCL, suggesting that the more heterogeneous genetic
setting of the latter group may be associated to a worse clinical
outcome. If this hypothesis is correct, one could postulate that the
ectopic activation of ALK provides dominant oncogenic inputs
(strong oncogenic addiction), sufﬁcient to induce cell transforma-
tion possibly in association with a limited number of additional
synergizing defects. On the contrary, ALK− ALCLs might require
the acquisition of a large number of tumorigenic defects, which
Table 2 | Clinical features of anaplastic large cell lymphoma compared
to peripheralT-cell lymphoma, not-otherwise specified (PTCL–NOS).
Disease
PTCL–NOS ALCL
DESCRIPTIONS
No. of cases 2,148 1,296
Mean age at diagnosis ±SD 58.4±19.0 50.5±22.0
5-Year RS (%) 38.7 54.8
DEMOGRAPHIC DISTRIBUTION
Non-Hisp W No. (%) 826 (38.5) 524 (40.4)
Age±SD 58.8±18.0 51.3±20.9
Hisp W No. (%) 122 (5.7) 121 (9.3)
Age±SD 46.8±18.8 40.9±23.7
Black No. (%) 170 (7.9) 97 (7.5)
Age±SD 51.5±17.0 46.9±17.0
AI/API No. (%) 139 (6.5) 49 (3.8)
Age±SD 59.0±19.6 43.2±23.1
Non-Hisp W indicates Non-Spanish–Hispanic–Latino White; Hisp W indicates
Spanish–Hispanic–LatinoWhite; AI/API indicates American Indian/AK Native and
Asian/Paciﬁc Islander.
could accumulate overtime resulting in a highly heterogeneous
karyotype.
Morphologically ALCLs can be divided in ﬁve morphologic
variants (a common, giant cell-rich, lympho-histiocytic, small-cell
type, and Hodgkin-like, with the common variants corresponding
to the lesions originally described by Stein et al., 2000). Cyto-
logically, the neoplastic cells show a wide spectrum, although all
cases have a variable proportion of “hallmark cells” (Benharroch
et al., 1998; Jaffe, 2001; Figure 1). These are large lymphocytes
with “horse shoe” or “kidney shaped” nuclei and abundant cyto-
plasm. ALCLs have a unique immunophenotype characterized by
the strong expression of the CD30 antigen, a cytokine recep-
tor of the tumor necrosis factor receptor superfamily, with a
membranous pattern often associated with reinforcement stain-
ing within the Golgi area. The neoplastic cells, which are of T-cell
origin, commonly lack many of the T-cell markers, although they
frequently express cytotoxic molecules such as granzyme B, per-
forin, and T-cell-restricted intracellular antigen-1 (TIA1). More-
over, ALK+ ALCLs frequently display phosphorylated peptides
including pSHP2 and pSTAT3 (Table 3).
ANAPLASTIC LYMPHOMA KINASE
Anaplastic lymphoma kinase is a tyrosine kinase receptor (TKR),
with an extracellular ligand-binding domain, a transmembrane-
spanning region and an intracellular tyrosine kinase domain. It
belongs to the Insulin Receptor superfamily and is closely related
to the leukocyte tyrosine kinase (LTK). The overall structure of
ALK has been conserved through evolution; this is particularly the
case for the kinase domain, which is highly homologous among
a variety of species, even though some differences, including the
Tyr1604, have been found, suggesting peculiar functions in dif-
ferent species and/or in unique pathological settings (Bai et al.,
1998).
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FIGURE 1 | Anaplastic large cell lymphoma.The neoplastic cells of
ALCL typically show a broad spectrum of morphologic features, and
virtually all cases display a variable proportion of “hallmark cells.” The
CD30 antigen, a cytokine receptor of the tumor necrosis factor
receptor superfamily, is strongly expressed by all ALCL often in
association with perforin, granzymes andT1A1 antigens. Alk
expression is detected only in a subset of ALCL as result of
translocations involving the ALK gene.
Table 3 | Immunophenotypic and genomic features of ALCL.
ALCL
ALCL ALK+ ALCLALK−
IMMUNOPHENOTYPIC FEATURES
CD30 +++ +++
CD2 + ++
CD3 −/+ +
CD4 +/++ +/++
CD8 + +
CD43 +/++ +/++
CD56 −/+ −/+
TIA1, granzyme B, or perforin +++ +++
NFTAC − −
pSHP2 +/++ −/+
p-STAT3 +++ +
C/EPBβ +++ +
PDGFRα −/+ −/+
EMA +++ ++
CD15 −/+ −/+
PAX5 − −
GENETICS
TCR γ/β +++ +++
IgH/L − −
EBV − −
+++, X>75%; ++, 50%<X<75%; +, 25%<X<50%; −/+, X<25%. −,
X=0%.
The physiological role of ALK has been only partially deﬁned.
In C. elegans and Drosophila, the loss of ALK results in defects
in midgut development, neuronal wiring, and plasticity. In adult
mice, the genomic deletion of ALK has subtle or no phenotype,
although its expression is upregulated after neuronal injuries
enhancing the regeneration of myelinated axons (Mi et al., 2007).
Recent data have been conﬁrmed that loss of ALK signaling results
in a dramatic decrease in newborn neurons in young as well as
adult mice, as in Drosophila where ALK protects larval neuroge-
nesis from nutrient stress (Cheng et al., 2011). Interestingly, ALK
in mammals appears to enhance cognitive performance as well
(Weiss et al., 2012).
In ALCLs, the ALK gene is inappropriately expressed in lym-
phoid cells as a result of several translocations, in which the
intracytoplasmic region of the gene, coded by the exons 20–
29 (NM_004304.3), is fused with different partners that provide
dimerization domains (Table 4; Pulford et al., 2001; Chiarle et al.,
2008b). The most common of these translocations is the t(2;5;
p23;q35) that leads to the nucleophosmin (NPM)–ALK fusion
protein (Chiarle et al., 2008b). Alternative translocations of ALCL
have been discovered involving various partners, including the
TPM (Lamant et al., 1999), TFG (Hernandez et al., 1999, 2002),
ATIC (Colleoni et al., 2000), TSPYL2 (Touriol et al., 2000), MSN
(Tort et al., 2001), KIAA1618 (Cools et al., 2002), VCL (Debe-
lenko et al., 2003), MYH9 (Lamant et al., 2003), KIFB5 (Wong
et al., 2011; Takeuchi et al., 2009). Notably, ALK+ ALCL often
display additional alterations involving many chromosomes (dele-
tions:4, 9p, 10p, 11q, and 13q, and gains: 1q, 7p, 6p, 17p, and
17q; Ott et al., 1998; Zettl et al., 2004; Salaverria et al., 2008),
although common discrete secondary lesions have not been dis-
covered yet. Moreover, using conventional genomic approaches,
and more recent next generation sequencing from fresh and/or
parafﬁn embedded tissue samples have shown new translocation
of ALK in many types of human cancers (Table 4; Jung et al.,
2012; Lipson et al., 2012; Takeuchi et al., 2012; Togashi et al.,
2012).
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Table 4 | Recurrent chromosomal translocations involving the ALK gene in human cancers.
Disease Chromosomal
abnormalities
Fusion protein
(kDa)
Partner Frequency
(%)
ALK IHC
staining
Reference
ALCL t(2;5)(p23;q35) NPM–ALK (80) NPM1 75–80 Cyto/nuclear Morris et al. (1994), Shiota et al. (1994)
ALCL t(2;17)(p23;q25) ALO17–ALK (ND) ALO17 <1 Cyto Cools et al. (2002)
ALCL t(2;3)(p23;q21) TFG–ALK (113) TFG 2 Cyto Hernandez et al. (1999, 2002)
ALCL t(2;X)(p32;q11–12) MSN–ALK (125) MSN <1 Cyto Tort et al. (2001, 2004)
ALCL t(1;2)(q25;p23) TPM3–ALK (104) TPM3 12–18 Cyto Lamant et al. (1999), Siebert et al. (1999)
ALCL t(2;19)(p23;p13) TPM4–ALK (95) TPM4 <1 Cyto Meech et al. (2001)
ALCL inv(2)(p23;q35) ATIC–ALK (96) ATIC 2 Cyto Ma et al. (2000), Trinei et al. (2000), Colleoni et al.
(2000)
ALCL t(2;22)(p23;q11.2) MYH9–ALK (220) MYH9 <1 Cyto Lamant et al. (2003)
ALCL t(2;17)(p23;q23) CLTC1–ALK (250) CLTC1 2 Cyto Touriol et al. (2000)
DLBCL t(2;5)(p23;q35) NPM–ALK (80) NPM1 N/A Cyto/nuclear Adam et al. (2003), Onciu et al. (2003)
DLBCL t(2;17)(p23;q23) CLTC1–ALK (250) CLTC1 N/A Granular cyto De Paepe et al. (2003)
DLBCL t(2;5)(p23.1;q35.3) SQSTM1–ALK (ND) SQSTM1 N/A Cyto Takeuchi et al. (2011)
DLBCL ins(4)(2;4)(?;q21) SEC31A– SEC31A N/A Cyto Bedwell et al. (2011), Van Roosbroeck et al. (2010)
t(2;4)(p24;q21) ALK (ND)
IMT t(1;2)(q25;p23) TPM3–ALK (104) TPM3 50 Cyto Lawrence et al. (2000)
IMT t(2;19)(p23;p13) TPM4–ALK (95) TPM4 <5 Cyto Lawrence et al. (2000)
IMT t(2;17)(p23;q23) CTLC–ALK (250) CLTL <5 Cyto Bridge et al. (2001), Patel et al. (2007)
IMT inv(2)(p23;q35) ATIC–ALK (96) ATIC <5 Cyto Debiec-Rychter et al. (2003)
IMT t(2;11;2) CARS–ALK CARS <5 Cyto Cools et al. (2002), Debelenko et al. (2003)
(p23;p15;q31) (ND)
IMT t(2;2)(p23;q13) RANBP2– RANBP2 <5 N/M Ma et al. (2003), Marino-Enriquez et al. (2011)
inv(2)(p23;p15;q31) ALK (ND)
IMT t(2;4)(p23;q21) SEC31L1–ALK (ND) SEC31L1 <5 Cyto Panagopoulos et al. (2006)
ESCC t(2;19)(p23;p13) TPM4–ALK (110) TPM4 N/A Cyto Jazii et al. (2006), Du et al. (2007)
RCC t(2;10)(p23;q22) VCL–ALK (117) VCL N/A Cyto Debelenko et al. (2011)
NSCLC inv(2)(p21;p23) EML4–ALK (120) EML4 2–5 Cyto Rikova et al. (2007), Soda et al. (2007)
NSCLC t(2;3)(p23;q21) TFG–ALK (113) TFG 2 Cyto Rikova et al. (2007)
NSCLC t(2;10)(p23;p11) KIF5B–ALK (ND) KIF5B <1 Cyto Takeuchi et al. (2009), Wong et al. (2011)
NSCLC t(2;14)(p23;q32) KLC1–ALK (ND) KCL1 <5% Cyto Togashi et al. (2012)
NSCLC t(2;9)(p23;q31) PTPN3–ALK (ND) PTPN3 N/A Cyto Jung et al. (2012)
CRC inv(2)(p21;p23) EML4–ALK (120) EML4 <5% Cyto Lin et al. (2009)
CRC t(2;2)(p23.3) C2orf44–ALK (ND) C2orf44 N/A Cyto Lipson et al. (2012)
BC inv(2)(p21;p23) EML4–ALK (120) EML4 <5% Cyto Lin et al. (2009)
ND, not determined; Cyto, cytoplasmic; N/M, nuclear/membrane; N/A, non-assessed; ALCL, anaplastic large cell lymphoma, DLBCL, diffuse large B-cell lymphoma;
IMT, inﬂammatory myoﬁbroblastic tumor; ESCC, esophageal squamous cell cancer; RCC, renal cell cancer; NSCLC, non-small-cell lung cancer; CRC, colon–rectal
cancer; BC, breast cancer.
ALK SIGNALING
Understanding how ALK signals and deﬁning the mechanisms
responsible for its deregulation are critical to dissecting how
ALK mediates cellular transformation and provides the basis for
“intelligent” therapeutic approaches.
An area of debate remains on how the ALK receptor phys-
iologically signals in mammals. Contrary to Drosophila in
which the dALK ligands have clearly been identiﬁed (Palmer
et al., 2009), in mammals several hypothetical ligands have been
considered, among them are: PTN (pleiotrophin or HB-GAM),
OSF-1(osteoblast-speciﬁc factor-1), HARP (heparin afﬁnity reg-
ulatory peptide), HBNF (heparin-binding neurotrophic factor),
and MK (midkine). Nevertheless the role of these molecules
remains controversial and it is plausible that other, so far unknown
ALK ligands, may exist. It can also be contemplated that some of
the current ligands, such as PTN, may function indirectly inhibit-
ing alternative molecules like the phosphatase RPTPβ/ζ, provid-
ing a higher steady state phosphorylation status of the receptor
(Perez-Pinera et al., 2007).
The ectopic expression of ALK chimera leads to their hetero-
and homo-dimerization, via the dimerization domains of ALK
partners resulting in a constitutive activation of the intracyto-
plasmic catalytic domain. This results in the constitutive acti-
vation of multiple signaling pathways, which lead to cell trans-
formation and sustains the neoplastic phenotype (Chiarle et al.,
2008b). In NPM–ALK ALCL, the N-terminus region of NPM1
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provides the dimerization domain essential for the chimera’s auto-
phosphorylation.NPM1 is amultifunctional protein,which acts as
a molecular chaperone in the transport of pre-ribosomal particles
from the nucleus to the cytoplasm, but it functions in addition
to DNA repair, transcription, and genomic stability regulation
(Okuwaki, 2008).
It is well established that the forced expression of ALK chimeras
has oncogenic potential in in vivo as well in vitro models (Kuefer
et al., 1997; Bai et al., 1998; Chiarle et al., 2005; Turner andAlexan-
der, 2005). In vivo the constitutive expression of ALK transgenic
cassettes under hematopoietic promoters can drive B- or T-cell
transformation, providing a valuable tool for the study of ALCL
(Chiarle et al., 2003;Turner andAlexander, 2005) and for the set up
of innovative chemotherapeutic modalities (Cheng et al., 2012).
Similar ﬁndings have been recently obtained expressing EML4–
ALK (Soda et al., 2008) or TFG-1–ALK fusion proteins under
lung-restricted promoters.
The transforming properties and the signaling elicited by ALK
fusion proteins have been extensively studied using a variety of
genetic, proteomics, and pharmacological approaches. Overall,
as in many other oncogenic kinases, the deregulated expression
of ALK leads to the simultaneous activation of many signaling
pathways, which have been proven to synergistically provide the
required signals for the maintenance of the neoplastic phenotype.
Indeed, the ablation of the ALK signaling, at least in lymphoid
cells, demonstrates the absolute ALK oncogenic “addiction” of
these tumors (Piva et al., 2006; Wan et al., 2006; Christensen et al.,
2007; Galkin et al., 2007). It is unclear which further defects may
contribute in ALK+ ALCL, although it is proven that the forced
expression of ALK chimera in normal cells leads to senescence
(Martinelli et al., 2011) and that ALK+ lymphoma in Tg mice
require a few months to occur, suggesting that a combination of
lesions is acquired. Remarkably, the activation of IGF-IR can con-
tribute to the neoplastic phenotype of ALK+ ALCL cell lines (Shi
et al., 2009). More importantly, in the case of ALK+ NSCLC cell
lines,ALK addiction has been proven to be variable and the patho-
genetic role of other kinase receptors have been suggested in these
settings (Koivunen et al., 2008). The determination of the ALK
dependency and the contribution of other co-signaling kinase(s) is
critical for deﬁning the most effective chemotherapeutic regimen
in each patient. Thus in selected settings, it may be necessary not
only to dissect the presence of any given oncogenetic defect (i.e.,
EGRF, k-Ras mutation etc.) but to also quantify the levels of the
activation of critical targetable molecules as well.
Mutagenesis and functional studies have identiﬁed a plethora
of NPM–ALK interacting molecules which ultimately lead to the
activation of key pathways including RAS/Erk, PLC-γ, PI3K, and
Jak/signal transducers and activators of transcription (STAT)path-
ways, which in turn control cell proliferation and survival and
cytoskeletal rearrangements (Figure 2).
Ras/Erk PATHWAY
The increased growth of ALK+ ALCL cells is believed to be largely
dependent on the activation of the Ras/Erk pathway (Fujimoto
et al., 1996; Pulford et al., 2001). In NPM–ALK several adaptors
or scaffolding molecules with Src-homology 2 (SH2) or phos-
photyrosine binding (PTB) domains can bind and activate the
Ras/Erk pathway. Although, SHC, IRS1, and Grb2 bind directly
to NPM–ALK, neither SHC nor IRS1 are essential for transfor-
mation, since loss of their ALK docking sites does not preclude
cell transformation (Fujimoto et al., 1996). Grb2 binds to differ-
ent regions of NPM–ALK, mainly Tyr(152–156), Tyr(567), and a
proline-rich region, Pro(415–417), and primarily regulates ALK-
mediated phosphorylation of SHP2, which plays a key role in
ALCL cell growth (Riera et al., 2010). The concomitant down-
regulation of ERK-1 and ERK-2 in ALK+ ALCL using RNAi or
speciﬁc Mek inhibitors leads to a cell cycle arrest in absence of an
increased rate of apoptotic cells (Marzec et al., 2007). Ras activa-
tion via MAPK (mitogen-activated protein kinases), and ERK-1
and 2, regulates several AP-1 transcription factors, which are
believed to contribute to the ALCL neoplastic phenotype (CD30;
Watanabe et al., 2005; Hsu et al., 2006; Staber et al., 2007), reg-
ulate cytotoxic molecule expression (Pearson et al., 2011) and
they are required for ALK-mediated transformation in mouse
models.
PCL-γ PATHWAY
PLC-γ, docking in position Y664 of NPM–ALK, induces the
hydrolysis of phosphatidylinositol (PIP2) into inositol triphos-
phate (IP3) and diacylglycerol (DAG), molecules that can mod-
ulate the release of Ca2+ from intracellular compartments and
activates the serine/threonine protein kinase C (PKC). The patho-
genetic role of this pathway has been documented in Ba/F3 cells
(a pro-B line that requires IL-3 for survival and growth), which
can overcome IL-3 requirements in presence of the ectopic NPM–
ALKwt but not NPM–ALKY664F (Bai et al., 1998). Interestingly, the
PLC-γ docking site (Y664) is present only in the human ALK but
not in the mouse gene, suggesting a unique function in human
ALK-mediated transformation.
PI3K PATHWAY
NPM–ALK interact directly and most likely indirectly with PI3K
(Bai et al., 2000). The ALK–PI3K interaction (catalytic p110 sub-
unit) leads to the activation of the PKB/AKT and the subsequent
downstream signaling events. These play a critical role in ALK-
mediated transformation, as originally demonstrated by the dom-
inant negative PKB/Akt approach (Slupianek et al., 2001) and by
up-regulation of cyclin D2 and down-regulation of Bim-1 and
p27 via hyperphosphorylation of the transcription factor FOXO3a
afterALK forced expression (Guet al., 2004). Finally thePI3K/AKT
signalingpathwayhas been shown recently to control thephospho-
rylation levels of GSK3β, upregulating the expression of MCL-1
and Cdc25A, which may contribute to the neoplastic phenotype
(Mcdonnell et al., 2011).
c-SCR PATHWAY
c-Src, a TKR, plays a relevant role in ALCL cell migration, as well
as in cell proliferation and growth. c-Src that is normally main-
tained in a catalytically inactive conformation can be activated by
NPM–ALK and it is required to sustain ALCL cell growth (Cussac
et al., 2004). Src-family kinases may also contribute to VAV-1 sig-
naling, leading to a sustained activation state of Cdc42. Cdc42 and
p130C as in this context regulates ALCL cell shape and migration
(Ambrogio et al., 2008).
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FIGURE 2 | Anaplastic lymphoma kinase signaling.The ectopic
expression of ALK fusion proteins leads to the constitutive activation of
the tyrosine kinase, and concomitant activation of multiple signaling
pathways. ALK, via a direct binding of IRS1, Shc, and Src on speciﬁc
tyrosine residues, is a strong activator of the Ras/Mek/Erk-1/2 extracellular
signal-regulated kinase (Erk) pathway that provides key mitogenic
signaling. Ras/Erk pathways, via multiple AP-1 transcription factors, up
regulates the CD30 expression. Mitogen-induced extracellular kinase
(MEK)/ERK signaling pathway results in phosphorylation of mTOR which in
turn leads to the phosphorylation of several critical targets (p70S6K and
S6rp, eukaryotic initiation factor 4E (eiF4E)–binding protein-1 (4E-BP1).
Activation of mTOR is also achieved through the synergist activation of the
phosphatidylinositol 3-kinase (PI3K) pathway as result of the activation of
Akt1/2 molecules. In the case of PLC-γ, this protein is directly activated by
ALK (Y664) and capable of triggering pro-mitogenic stimuli generating
diacylglycerol and IP3, which leads to the activation of PKC, and
mobilization of calcium stores from the endoplasmic reticulum as well. As
for many other cells, activated Akt1/2 enhance ALCL cell survival by
blocking the function of pro-apoptotic proteins, such as BAD and indirectly
regulate key cell cycle regulators (BIM-1, p27, and cyclinD2) via FOXO3A.
Negative regulation of p-GSK3β leads to the up-regulation of Mcl-1 and
CDC25A which confers the advantage of growth and protection from
apoptosis. Stat3 regulated molecules are essential and required for the
maintenance of the ALK-mediated neoplastic phenotype of ALCL cells.
ALK fusion proteins can directly phosphorylate STAT3, alternatively JAK2/3
can also synergize. Negative regulators of this pathway may impose their
action by dephosphorylating ALK itself and/or receptor-associated kinases
(Src and JAK). Notably, methylation of the promoter region of SHP1 has
been reported in ALK+ ALCL cells, resulting in the down-regulation of its
expression and thus an overall enhancement of STAT3 signaling. Activation
of STAT3 is associated with a speciﬁc signature (∼1500 genes), which
includes several transcription factors (i.e., CEBP/β), cell cycle (i.e., Cyclin D,
c-myc etc.), survival/apoptosis molecules (Bcl-A2, Bcl-XL, Survivin, MCL-1)
and cell adhesion, and mobility proteins.
Jak/STAT PATHWAY
Signal transducers and activators of transcription proteins are a
family of transcription factors ﬁrst characterized for their role
in cytokine signaling. These proteins contain a site for spe-
ciﬁc tyrosine phosphorylation, which after modiﬁcation results
in a conformational rearrangement and dimerization through
phosphotyrosine–SH2domain interactions.Once STATs are phos-
phorylated, they dimerize and accumulate in the nucleus (Levy
and Inghirami, 2006). Alternative non-canonical properties have
recently been described for STAT3 (Reich, 2009). The patho-
genetic role of both STAT3 and STAT5 have been demonstrated
in ALK+ ALCL, although the oncogenic contribution of STAT5 is
less clear and most likely linked to the unique experimental mod-
els (Nieborowska-Skorska et al., 2001). Indeed, in either T (Zamo
et al., 2002; Zhang et al., 2002; Amin et al., 2004) or B (Momose
et al., 2009) ALK+ lymphoma p-STAT3 species are most com-
monly expressed and in ALCL, ALK signaling via STAT3 represses
STAT5 expression (Zhang et al., 2007).
The constitutive activation of STAT3 is achieved through mul-
tiple mechanisms, such as NPM–ALK which can directly phos-
phorylate STAT3 as well as JAK3 that can indirectly contribute,
as demonstrated by reduce levels of p-STAT3 after its pharmaco-
logical inhibition (Amin et al., 2003). Moreover primary ALCL
can display a loss of JAK/STAT pathway negative regulator Shp1
(Honorat et al., 2006) or alternatively demonstrate an overexpres-
sion of protein phosphatase 2A, capable of sustaining a STAT3
phosphorylation status (Zhang et al., 2002).
The critical role of STAT3 in ALK+ ALCL models is well estab-
lished since its knockdown by RNAi invariably leads to ﬁrst cell
cycle arrest (Amin et al., 2004; Piva et al., 2006), followed over
time by the execution of irreversible apoptotic program. This
phenomenon is associated with well-deﬁned changes in transcrip-
tion and the reproducible modulation of a large number of genes
(∼1500), many of which are physiologically down-regulated in
the presence of active p-STAT3. Most of these changes can be
observed using anti-ALK inhibitors or anti-ALK RNAi, demon-
strating that “oncogenic addiction” of ALK+ ALCL cells requires
a STAT3-mediated transcription. Moreover some of these genes
can be used as molecular classiﬁers and may became diagnostic
tools for the identiﬁcation ALCL among primary T-NHL (Chiarle
et al., 2008b; Piva et al., 2010). To discover the STAT3 transcrip-
tionally regulated genes, we have recently conducted time kinetics
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experiments, demonstrating that only a limited number of known
andunknownSTAT3 genes are directlymodulated inALCL. These,
however, can lead to a cascade of downstream changes. Inter-
estingly enough, this STAT3 dependent phenotype requires the
concomitant activation of multiple genes, as demonstrated by the
individual knockdown by siRNA and/or the activation of a unique
miRNA cluster(s). Intriguingly, in ALK+ NSCLC cell lines the
STAT3-associated gene expression signature shares a very limited
number of targets with that of ALCL, suggesting that STAT3 onco-
genic requirements are lineage restricted and/or cell dependent, as
shown by the mild phenotype associated with the knockdown of
STAT3 in ALK+ NSLCL cells lines (Takezawa et al., 2011).
STAT3 activation controls cell cycle, apoptosis and DNA dam-
age, adhesion and motility, G protein signaling, inﬂammation
and immune response, metabolic pathways, and angiogenesis.
Increased expression of many anti-apoptotic molecules, such as
Bcl2, Bcl-XL, Survivin, and Mcl-1 proteins, that in association
with ALK-regulated genes such as BCL2A1, provide strong anti-
apoptotic signals (Amin et al., 2004;Piva et al., 2006).Uncontrolled
proliferation is in part regulated through cyclin D3 (Dalton et al.,
2005) and c-myc (Amin et al., 2003). Finally several studies have
shown how ALK–STAT3 may control angiogenesis (Marzec et al.,
2011) and regulate key immune functions (Marzec et al., 2008).
Lastly, STAT3 is in part responsible for the null phenotype of
ALK+ ALCL, determining T-cell identity and signaling (Zhang
et al., 2002; Ambrogio et al., 2009). The strict requirement for
STAT3 activation inALK+ALCL makes this molecule an ideal tar-
get particularly in the context of mutated ALK chimera, resistant
to anti-ALK small molecules. Indeed, small selective compounds
like S3I-201, niclosamide, and the pyrimethamine show potent
apoptotic effects against ALK+ ALCL cells.
Finally, through proteomic studies many molecules were iden-
tiﬁed and proven to contribute to the neoplastic phenotype
protecting from apoptosis (Bassermann et al., 2005), promot-
ing cell cycle, transport, and transcription activities (Sjostrom
et al., 2007). Interestingly, this approach has conﬁrmed the dis-
covery of novel ALK chimera and the deﬁnition of a new sub-
set of NSCLC tumors (Rikova et al., 2007). Using quantita-
tive proteomic-based approaches coupled with an enrichment
strategy that allows the identiﬁcation speciﬁc phosphorylation
sites within peptides, we have shown that 5-aminoimidazole-4-
carboxamide ribonucleotide formyltransferase/IMP cyclohydro-
lase (ATIC) is phosphorylated at Y104 via ALK and that ALK-
mediated ATIC phosphorylation enhances its enzymatic activity,
dampening the methotrexate-mediated transformylase activity
inhibition (Boccalatte et al., 2009).
Many of the information provided above have been derived
using ALK+ ALCL cell lines harboring the NPM–ALK chimera.
It is postulated that the ALK-mediated transformation of differ-
ent fusion proteins may be imposed through analogous mech-
anisms. Indeed, many of the ALK fusions can elicit similar sig-
nals. Although, they share dimerization domains, which allow the
constitutive activation of the proteins, different partners display
unique features and impose speciﬁc intracellular localization to
theALK proteins. This implies that each of them may have unique,
yet slightly different properties, whose contribution(s) to the neo-
plastic phenotype remain yet to be clariﬁed. Toward this end, it
has been proven that some fusions display a higher migratory and
invasive capacity in vitro and in vivo (Armstrong et al., 2004). The
clariﬁcation of these features may be critical in the understanding
of the oncogenic potential and oncogenic properties of different
ALK fusion proteins in human cancers.
TARGETED THERAPY
The discovery that EML4–ALK fusions can be found inNSCLChas
dramatically changed the landscape of ALK, fostering innovative
therapies to move very rapidly into the clinical ﬁeld. Remarkably,
the data generated in ALCL and inﬂammatory myoﬁbroblastic
tumors (IMT), although providing the intellectual/scientiﬁc bases
for the design of drug discovery programs, have not generated
sufﬁcient interest fromeither thepharmaceutical or scientiﬁc com-
munities. This perception has deﬁnitively changed when (Soda
et al., 2007) ﬁrst described ALK translocations in a set of lung can-
cers. Since then, we have found that many other human cancers
carry ALK lesions in a well-deﬁned subset of patients, making the
"ALK story" one of the most attractive and promising of the last
decade. Ultimately, the discovery that sporadic as well as familiar
neuroblastoma can carry ALK activating mutations has opened
additional hopes and new avenues. This has led to the production
of different ALK inhibitors that are now in one stage or the other
of investigation, with the Crizotinib as the ﬁrst approved drug
for the treatment of lung cancer patients. Although we have wit-
nessed tremendous advances in a very short period of time, many
issues remain ahead. These include the design of the most effec-
tive chemotherapeutic combinations, the deﬁnition of the right
combinations for every individual patient, the discovery, early
on during treatment, of non-responder patients, and ﬁnally new
modalities for overpassing the inevitable resistance associatedwith
the usage of anti-ALK inhibitors.
We believe that many of these issues could be solved once a sys-
tematic molecular stratiﬁcation is employed in all cancer patients.
The recent application of Next Generation Sequencing in lung and
colon cancer has not only showed that novel translocations (Lip-
son et al., 2012) can be discovered among these tumors but they
might provide the basis for identifying the molecular ﬁngerprints
responsible for the clinical behavior of individual cancers. This
will only be possible when the cost of these analyses are affordable
and when the data obtained by friendly bioinformatic modules are
immediately translated into daily clinical practice.
These and many other questions have been further discussed
in the accompanying manuscripts.
Here, we would like to address speciﬁc topics and discuss a few
alternatives.
POTENTIAL CHALLENGES
Indeed, we need to carry forward the progress that we have
gained in the NSCLC into the ﬁeld of ALCL, IMT, and neu-
roblastoma; despite the fact that these diseases represent only a
relatively small market and are rare orphan entities. Neverthe-
less, many of them occur in children and we have very little
therapeutic options for some of them. The usage of anti-ALK
inhibitors may provide a unique opportunity reaching relevant
clinical beneﬁts in the absence of substantial side effects. This is
critical in young individuals who may beneﬁt the most. Anti-ALK
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inhibitors and innovative approaches are required for refractory
or relapsed ALK+ ALCL after conventional treatment. The cur-
rently recommended protocol for these patients is an autologous
stem cell transplantation (HDC/ASCT) preceded by high-dose
chemotherapy in ﬁrst remission. Alternatively, a few experimen-
tal studies currently open are investigating the efﬁcacy of Bren-
tuximab vedotin (SGN-35) alone (NCT01352520, NCT0043084,
NCT00866047, etc.) or in combination with conventional drugs
(NCT00649584).
There are also clinical studies investigating the usage of Crizo-
tinib (CT00939770) or AP26113 (NCT01449461) ALK inhibitors
in these settings.
Finally, since kinase inhibitors are invariably associated to drug
resistance and they are incapable of eradicating stem cancer cells,
new approaches need to be contemplated. Although ALK signal-
ing is considered to be critical in many ALK+ ALCLs, we have
seen that co-synergizing signals may contribute to maintain the
neoplastic phenotype (in ALCL IGFR and in NSLCL EGFR, c-
Met etc.). These signals often converge on critical downstream
molecules, which could be targeted to improve the therapeutic
responses. For examples the concomitant treatment with ALK and
MEK inhibitors has been shown to increase apoptosis of ALK+
NSCLC cell line in vitro providing a rational approach for clinical
interventions (Tanizaki et al., 2012). Notably, the application of
geldanamycin-based HSP90 inhibitors has also been proven to be
efﬁcacious leading to the forced degradation of the wt or mutated
ALK fusion proteins (Chen et al., 2010; Katayama et al., 2011).
These and other ﬁndings (Bonvini et al., 2004) support clinical
trails in ALCL patients NCT00117988).
Moreover, since ALK represents a unique onco-antigen, being
required for tumor maintenance, expressed in limited tissue com-
partments and capable of eliciting relevant ALK-speciﬁc B and
T-cell responses in lymphoma patients (Pulford et al., 2000; Pas-
soni and Gambacorti-Passerini, 2003; Ait-Tahar et al., 2006, 2007;
Chiarle et al., 2008a), this provides the basis for the design and
implementation of immune-based therapies, which in association
with drug-based approaches could lead to the complete control
of the disease. Finally, immunological strategies [i.e., anti-CD25
(NCT00801918) anti-CD30 (Ansell et al., 2007; Forero-Torres
et al., 2009) and/or CD26 (Ho et al., 2001) antibodies], in com-
bination with conventional or small molecule approaches, are
currently considered to enhance anti-tumor responses or to gain
the complete eradication of cancer cells.
FUTURE DEVELOPMENTS
Since ALK oncogenic properties rely on the constitutive acti-
vation of multiple pathways, it is plausible that combinational
therapies may be designed including not only conventional drugs
but also small compounds capable of targeting key effectors
within ALK signaling pathways (Figure 2). Toward this end, the
usage of compounds already in clinics for other applications,
but recently discovered to have anti-STAT3 activities, are par-
ticularly appealing. These include for example niclosamide and
pyrimethamine currently used as anthelmintic or anti-parasitic
compounds (Takakura et al., 2011), which display promising
therapeutic efﬁcacies in ALK+ ALCL models. Analogously, it is
also plausible to consider a set of compounds known to down-
regulate members of the Ras-Erk pathway. The most promising
are represented by the Mek inhibitors (i.e., AZD6244, PD-325901,
GDC-0973 etc.), which can lead to ALCL cell cycle arrest and in
combination with anthracycline can become powerful treatment
modalities. The inhibitor of PI3K and mTOR (Turturro et al.,
2002; Marzec et al., 2007; Staber et al., 2007) have also been pro-
posed and in some cases anti-ALK, HSP90 or mTOR inhibitors
have proven to be quite efﬁcacious (Chen et al., 2010; Lovly et al.,
2011). Finally, since ALK+ ALCL display a strong expression of
BCL2A-138, it is reasonable to propose the usage of BH3 mimetic
drug as single or in combination with conventional compounds
as previously reported for the treatment of B-cell NHL (Paoluzzi
et al., 2008a,b; Stolz et al., 2008).
Thus, the armamentarium that we have in our end has become
very extensive requiring a systematic analysis of all possible com-
binations. This implies the set up of novel in vitro as well in vivo
models, which faithfully recapitulate the human clinical scenario.
More importantly we need to develop a battery of biomarkers
capable of stratifying patients and predicting their clinical out-
come. Toward this end, the usage of humanized mouse models in
which tumor as well human host cells are reconstituting the host
represent the new frontier for drug discovery and personalized
oncology modalities (Shultz et al., 2007).
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